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ABSTRACT
Introduction: Tofacitinib is an oral Janus kinase
inhibitor for the treatment of rheumatoid arthritis (RA).
Tofacitinib monotherapy was previously shown to
inhibit structural damage, reduce clinical signs and
symptoms of RA, and improve physical functioning
over 24 months in methotrexate (MTX)-naive adult
patients with RA. In this post hoc analysis, we
compared efficacy and safety of tofacitinib in patients
with early (disease duration <1 year) versus established
(≥1 year) RA.
Methods: MTX-naive patients ≥18 years with active
RA received tofacitinib monotherapy (5 or 10 mg two
times a day, or MTX monotherapy, in a 24-month
Phase 3 trial.
Results: Of 956 patients (tofacitinib 5 mg two times a
day, n=373; tofacitinib 10 mg two times a day, n=397;
MTX, n=186), 54% had early RA. Baseline disease
activity and functional disability were similar in both
groups; radiographic damage was greater in patients
with established RA. At month 24, clinical response
rates were significantly greater in patients with early
versus established RA in the tofacitinib 5 mg two times
a day group. Both tofacitinib doses had greater effects
on clinical, functional and radiographic improvements
at 1 and 2 years compared with MTX, independent of
disease duration. No new safety signals were observed.
Conclusions: Treatment response was generally
similar in early and established RA; significantly greater
improvements were observed at month 24 with
tofacitinib 5 mg two times a day in early versus
established RA. Tofacitinib 5 and 10 mg two times a
day demonstrated greater efficacy versus MTX
irrespective of disease duration. No difference in safety
profiles was observed between patients with early or
established RA.
Trial registration number: NCT01039688; Results.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic auto-
immune disease characterised by synovial
inflammation and joint damage that may
lead to significant disability.1 The goal of
treatment is disease remission or, if remission
is unattainable, the lowest disease activity pos-
sible, to improve the signs and symptoms,
reverse functional disability and halt radio-
graphic progression.2
It has been reported that disease duration
has an impact on the effectiveness of treat-
ment, and that comprehensive early treat-
ment may offer an opportunity to preserve
physical function and prevent disability.3–6 It
has been postulated that the early stages of
RA may, therefore, offer a therapeutic
window of opportunity in which to prevent
joint damage from occurring;7 8 it has been
Key messages
What is already known about this subject?
▸ Previous studies suggest that the early stages of
rheumatoid arthritis (RA) may offer a therapeutic
window of opportunity during which it may be
possible to prevent joint damage.
▸ In methotrexate (MTX)-naive patients with RA,
tofacitinib monotherapy is associated with inhib-
ition of structural damage, reductions in clinical
signs and symptoms of RA and improvements
in physical functioning, over a period of
24 months.
What does this study add?
▸ Tofacitinib 5 mg two times a day appeared more
effective in achieving clinical outcomes in early
(disease duration <1 year) versus established RA
(disease duration ≥1 year).
▸ We observed that compared with MTX, tofaciti-
nib monotherapy (5 or 10 mg two times a day)
significantly improved signs and symptoms and
physical function, and inhibited the progression
of structural damage in MTX-naive patients
regardless of disease duration.
How might this impact on clinical practice?
▸ The diagnosis of RA should be made, and treat-
ment started, as early as possible after the
development of symptoms.
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suggested that this window may exist from 3 months to
2 years following the onset of symptoms.9 10 Much of the
evidence for this has been suggested by trials of conven-
tional synthetic disease-modifying antirheumatic drugs
(csDMARDs) and tumour necrosis factor inhibitors
(TNFi), which have demonstrated that their use in
patients with early RA is associated with better outcomes
than in patients with established RA.11–14
Tofacitinib is an oral Janus kinase inhibitor for the
treatment of RA. The efficacy and safety of tofacitinib 5
and 10 mg two times a day administered as monotherapy
or in combination with csDMARDs, mainly methotrexate
(MTX), in patients with active RA, has been demon-
strated in Phase 215–19 and Phase 320–25 trials of up to
24 months’ duration, and in long-term extension studies
with up to 84 months of observation.26 27
The ORAL Start study (NCT01039688)23 was a
24-month, Phase 3, randomised, double-blind, parallel-
group, multicentre study, which compared tofacitinib
monotherapy (5 or 10 mg two times a day) with MTX
monotherapy in MTX-naive adult patients with RA.23 The
results of the primary analysis are reported elsewhere.23
In brief, tofacitinib monotherapy was associated with stat-
istically significant reductions in radiographic progression
(measured using van der Heijde modified total Sharp
score (vdHmTSS)), reductions in clinical signs and symp-
toms of RA, and improvements in physical functioning
versus MTX monotherapy at month 6, with similar results
at months 12 and 24, thus demonstrating durability of
response.23 Safety observations were consistent with prior
Phase 2 and Phase 3 clinical trials of tofacitinib in patients
with RA, and included infections (eg, herpes zoster),
gastrointestinal disorders, lymphoma and other malig-
nancies; no new safety signals were identified.23
The objective of this post hoc analysis was to compare
the efficacy and safety of tofacitinib monotherapy in
MTX-naive patients with early or established RA in the
Phase 3 ORAL Start study. For the purposes of this ana-
lysis, early RA was defined as disease duration <1 year, and
established RA as disease duration ≥1 year from disease
diagnosis. These boundaries were chosen to be within the
window suggested by the literature, and allowed for an
even split of patient data between the two groups.
The ultimate goal of this analysis was to provide
insight into the optimal therapeutic window of oppor-
tunity during which tofacitinib may be used, thereby
improving clinical and radiographic outcomes for
patients with RA.
METHODS
Study design
This was a 24-month, randomised, Phase 3, double-blind,
parallel-group trial conducted in 151 centres worldwide.
The full methodology used in this study, with inclusion
and exclusion criteria, has been reported elsewhere.23
The study was conducted in accordance with applic-
able legal and regulatory requirements, as well as the
general principles set forth in the International Ethical
Guidelines for Biomedical Research Involving Human
Subjects, International Conference on Harmonization
Guidelines for Good Clinical Practice, and the
Declaration of Helsinki. The study protocol and
informed consent documentation were approved by the
institutional review board or independent ethics com-
mittee at each investigational centre. All patients pro-
vided written, informed consent.
Patients
Patients were aged ≥18 years, with a diagnosis of RA as
defined by American College of Rheumatology (ACR)
1987 criteria,28 and who had ≥3 distinct joint erosions
on posteroanterior hand and wrist or foot radiographs
(locally read), or a positive test for rheumatoid factor, or
antibodies to cyclic citrullinated peptide. Eligible
patients also had ≥6 painful or tender joints, ≥6 swollen
joints and an erythrocyte sedimentation rate (ESR)
>28 mm/hour by Westergren method or high sensitivity
C reactive protein (hsCRP) levels >7 mg/L. Patients
were excluded if they received >3 weekly doses of MTX,
or if ≤3 weekly doses had been received but MTX had
been stopped due to an MTX-related adverse event
(AE). Patients were randomised in a 2:2:1 ratio to one of
three parallel treatment arms: tofacitinib 5 mg two times
a day, tofacitinib 10 mg two times a day or MTX weekly.
MTX was initiated at a dose of 10 mg/week and, if well
tolerated, increased by 5 mg/week every 4 weeks up to
20 mg/week by week 8 for the duration of the study.
We performed a post hoc subgroup analysis using the
final 24-month data in patients with early and estab-
lished RA.
Efficacy of treatment
Effects on signs and symptoms of RA were evaluated
using ACR response rates (ACR20, ACR50 and ACR70)
and Disease Activity Score in 28 joints (DAS28-4(ESR)
<2.6 (remission) and ≤3.2 (low disease activity)).
Physical function was assessed using the Health
Assessment Questionnaire-Disability Index (HAQ-DI), in
which a score <0.5 is considered a normal value, 0.5 to
≤1 mild-to-moderate disability, >1 to ≤2 moderate-to-
severe disability and >2 to 3 severe/very severe disability.
Joint structural preservation was assessed using the
vdHmTSS29 (range 0–448), with higher scores indicating
greater joint structural damage, and an evaluation of the
proportion of patients with no radiographic progression,
defined as change from baseline in vdHmTSS≤0.5.
In order to assess the sensitivity of findings on the
selection of the time points for defining early RA, key
efficacy parameters were also calculated for patients with
disease duration <6 and ≥6 months.
Safety
The incidence and severity of all AEs was recorded, as
previously described.23 The incidence of treatment-
emergent AEs (TEAEs), discontinuations due to AEs,
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AEs of special interest (SIEs), serious AEs (SAEs) and
deaths were compared in patients with early and estab-
lished RA.
Statistical analyses
Unless otherwise stated, efficacy analyses were based on
the Full Analysis Set, which included all patients who
received at least one dose of study drug and for whom
data were available from at least one postbaseline assess-
ment. Binary end points (eg, achievement of ACR20
response) were compared between tofacitinib (5 or
10 mg two times a day) and MTX in a post hoc analysis
using the normal approximation to the binomial distri-
bution. Missing values were computed using the non-
responder imputation method. Continuous end points,
such as change from baseline in HAQ-DI scores, were
analysed using a linear mixed-effect model for repeated
measures. Treatment, visit, treatment-by-visit interaction
and baseline were included as fixed effects, and with
patients as a random effect. Estimates of mean changes
from baseline for each treatment, as well as mean differ-
ences versus MTX were obtained from the model as
least squares (LS) means, with corresponding SEs. For
vdHmTSS, missing values due to patient discontinuation
were linearly extrapolated based on the baseline value
and postbaseline value prior to discontinuation. The
binary variable of progression/non-progression was
obtained from linearly extrapolated imputation data.
Observed case data were used in any descriptive ana-
lyses. ORs with 95% CI, comparing early versus estab-
lished disease for each treatment group, were provided
for each end point of interest. If the 95% CI did not
contain the value 1.0, the difference between the two
groups was considered statistically significant at the 5%
significance level. No preservation of type I error or
multiple-comparisons correction was applied to p values,
as statistical significance defined as p<0.05 was explora-
tory in nature.
Analyses of safety data were based on observed cases.
Incidence rates (IRs; unique patients with events per
100 patient-years of observation) for SIEs were based on
the number of patients with an event, and the total
exposure time censored at time of event, death or dis-
continuation from the study, and compared between
treatment groups. Exact Poisson 95% CIs adjusted for
exposure time were calculated for IRs.
RESULTS
Demographics
Baseline patient demographics and disease character-
istics are summarised in table 1. Approximately half the
956 patients treated (54% (515/956)) had a disease dur-
ation of <1 year; the proportions of patients with RA of
duration <1 and ≥1 year were similar between treatment
groups (table 1). The majority of patients in the study
were women and Caucasian (table 1). Baseline disease
activity (DAS28-4(ESR), tender and swollen joint
counts) and functional disability (HAQ-DI) in each
treatment group were similar in patients with RA dur-
ation of <1 and ≥1 year, whereas baseline vdHmTSS and
erosion scores, as expected, were higher in patients with
longer duration of disease (table 1).
Clinical responses
ACR response rates, DAS28-4(ESR) <2.6 and DAS28-4
(ESR) ≤3.2 responses at month 24 were generally
numerically higher in tofacitinib-treated patients, both 5
and 10 mg two times a day, with early RA versus those
with established disease (figure 1). ACR response rates,
DAS28-4(ESR) <2.6 and DAS28-4(ESR) ≤3.2 responses
were generally statistically significantly higher in patients
treated with tofacitinib 5 or 10 mg two times a day com-
pared with MTX, irrespective of disease duration stratifi-
cation (figure 1). Similar trends in clinical responses
were observed at month 12, with higher response rates
in tofacitinib-treated patients with early versus estab-
lished disease, and higher response rates in patients
treated with tofacitinib 5 or 10 mg two times a day com-
pared with MTX, irrespective of disease duration stratifi-
cation (see online supplementary figure S1). Mean
DAS28-4(ESR) levels at months 12 and 24 are presented
in online supplementary table S1.
The mean improvement from baseline in HAQ-DI at
month 24 was numerically greater for tofacitinib-treated
patients (5 or 10 mg two times a day) with early RA
versus those with established disease (figure 1). The
mean improvement from baseline in HAQ-DI at month
24 was significantly greater for tofacitinib 10 mg two
times a day compared with MTX for both disease dur-
ation subgroups, and for tofacitinib 5 mg two times a
day for patients with early RA (figure 1). Mean improve-
ments from baseline in HAQ-DI were also numerically
greater for patients treated with tofacitinib 5 or 10 mg
two times a day in early RA compared with established
disease, at month 12 (see online supplementary figure
S1). Mean improvement from baseline in HAQ-DI was
greater at month 12 for both tofacitinib doses compared
with MTX, but achieved statistical significance only for
patients with early RA (p<0.001 for both tofacitinib 5
and 10 mg two times a day). Mean HAQ-DI scores at
months 12 and 24 are presented in online
supplementary table S1.
Radiographic assessments
There was significantly greater inhibition of radiographic
progression in patients with early RA who received tofa-
citinib 5 or 10 mg two times a day compared with MTX
at month 24; for patients with established RA, there was
numerically greater inhibition of radiographic progres-
sion in both tofacitinib groups versus MTX at month 24,
but the difference was statistically significant in the
10 mg two times a day group only (figure 2A).Within
treatment groups, changes from baseline in vdHmTSS
scores at month 24 were similar between patients with
early RA and established RA (figure 2A). The
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proportion of patients with no radiographic progression
at month 24 was greater versus MTX in those with early
RA who received tofacitinib 5 mg two times a day, and in
those with early and established RA who received tofaci-
tinib 10 mg two times a day (figure 2B). Within treat-
ment groups, the proportion of patients with no
radiographic progression at month 24 was similar
between patients with early RA and patients with estab-
lished RA (figure 2B). Findings at month 12 were
similar (see online supplementary figures S2A, B). Mean
vdHmTSS scores at months 12 and 24 are presented in
online supplementary table S1.
Treatment differences with tofacitinib versus MTX
Treatment differences (tofacitinib vs MTX) with 95%
CIs for all clinical and radiographic assessments at
month 24 are shown in figures 1–3. Across all end
points, treatment differences versus MTX were generally
larger for patients with early RA who received tofacitinib
(5 or 10 mg two times a day) than for corresponding
patients with established RA, although CIs overlapped
(figure 3).
In patients with early RA, differences in clinical end
points with tofacitinib (5 or 10 mg two times a day) were
statistically significant versus MTX (all p<0.01, except for
DAS28-4(ESR) <2.6 in patients who received tofacitinib
10 mg two times a day, p<0.05). For patients with estab-
lished RA, statistically significant treatment differences
were more frequently observed in the tofacitinib 10 mg
two times a day group (all comparisons statistically signifi-
cant vs MTX at the p<0.05 level), compared with the tofa-
citinib 5 mg two times a day group (four out of eight
comparisons were statistically significant vs MTX at the
p<0.05 level). For ACR responses, DAS28-4(ESR) <2.6 and
DAS28-4(ESR) ≤3.2, larger treatment differences for tofa-
citinib 5 mg two times a day versus MTX were observed in
patients with early RA versus established RA (figure 3).
Corresponding treatment differences at month 12 are pre-
sented in online supplementary figure S3.
For patients with early RA, differences in LS mean
change from baseline in vdHmTSS, and the proportion
of patients without radiographic progression, observed
with tofacitinib (5 or 10 mg two times a day) versus
MTX at month 24 were significant at the p<0.01 level
(figure 3). In patients with established RA, the LS mean
change from baseline in vdHmTSS with tofacitinib
10 mg two times a day was significant versus MTX at the
p<0.05 level, and the proportion of patients with no
radiographic progression was significant versus MTX at
the p<0.05 level with tofacitinib 5 and 10 mg two times a
day (p=0.0199 and p=0.0039, respectively). Treatment
differences for radiographic assessments at month 12
are presented in online supplementary figure S3.
Odds ratios for clinical and radiographic responses in
early versus established RA
At month 24, patients with early RA had numerically
greater odds of achieving ACR20, ACR50, ACR70,
DAS28-4(ESR) <2.6, DAS28-4(ESR) ≤3.2 and no radio-
graphic progression compared with those who had estab-
lished RA, regardless of the study treatment received,
with the exception of DAS28-4(ESR) <2.6 for tofacitinib
5 mg two times a day and ACR70 for MTX (figure 4).
These differences were significant in patients who
Table 1 Baseline patient demographics and disease characteristics by disease duration
Duration of RA
Tofacitinib 5 mg two
times a day
Tofacitinib 10 mg two
times a day MTX
Early
(n=201)
Established
(n=172)
Early
(n=207)
Established
(n=190)
Early
(n=107)
Established
(n=79)
Demographics
Female, n (%) 147 (73.1) 139 (80.8) 162 (78.3) 165 (86.8) 87 (81.3) 58 (73.4)
Caucasian, n (%) 135 (67.2) 104 (60.5) 131 (63.3) 135 (71.1) 77 (72.0) 50 (63.3)
Mean age, years 50.2 50.5 48.1 50.7 47.9 50.1
Mean disease duration, years 0.32 6.01 0.31 6.71 0.35 5.98
Disease characteristics*
TJC 26.0 25.2 25.2 25.0 24.7 26.4
SJC 15.9 16.7 16.0 15.1 17.4 16.0
vdHmTSS 8.6 31.6 5.0 31.4 7.8 27.8
Erosion score 4.5 14.4 2.8 15.5 4.4 13.9
HAQ-DI 1.47 1.62 1.49 1.51 1.49 1.57
DAS28-4(ESR) 6.53 6.72 6.52 6.57 6.53 6.70
hsCRP, mg/dL 22.7 22.7 21.0 19.5 24.9 27.3
RF positive, % 82.6 82.0 80.2 83.2 83.2 86.1
ACPA positive, % 85.1 84.9 82.6 79.5 79.4 96.2
Early RA was defined as disease duration <1 year, and established RA was defined as disease duration ≥1 year.
*Mean values, unless otherwise specified.
ACPA, anticyclic citrullinated peptide antibodies; DAS28-4(ESR), Disease Activity Score in 28 joints (erythrocyte sedimentation rate); HAQ-DI,
Health Assessment Questionnaire-Disability Index; hsCRP, high sensitivity C reactive protein; MTX, methotrexate; n, number of patients; RA,
rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; vdHmTSS, van der Heijde modification of the
total Sharp score.
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received tofacitinib 5 mg two times a day for ACR20,
ACR50, ACR70, DAS28-4(ESR) <2.6 and DAS28-4(ESR)
≤3.2 (figure 4A). The corresponding 95% CI of the OR
for no progression in vdHmTSS with tofacitinib 5 mg
two times a day included 1 (figure 4A). For patients
receiving tofacitinib 10 mg two times a day or MTX,
95% CI for ORs included 1.0 for all clinical and radio-
graphic parameters (figure 4B, C). At month 12, similar
trends were observed in the tofacitinib 5 mg two times a
day treatment group; however, the 95% CI did not
include 1.0 for ACR70 and DAS28-4(ESR) <2.6, indicat-
ing statistical significance. ORs for clinical and radio-
graphic assessments at month 12 are shown in online
supplementary figure S4.
Sensitivity analysis
At month 24, patients with disease duration of
<6 months who received tofacitinib (5 or 10 mg) had
Figure 1 Clinical response in patients with early and established RA at month 24. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001
vs MTX within disease duration category. Early and established RA are defined as disease duration <1 and ≥1 year, respectively.
ACR, American College of Rheumatology response criteria; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte
sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; LS, least squares; MTX, methotrexate; RA,
rheumatoid arthritis.
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higher ACR response rates (with the exception of
ACR20) and rates of DAS28-4(ESR) <2.6 and DAS28-4
(ESR) ≤3.2 than those who had a disease duration of
≥6 months. In addition, ACR response rates, DAS28-4
(ESR) <2.6 and DAS28-4(ESR) ≤3.2 responses were
higher in patients treated with tofacitinib 5 or 10 mg two
times a day compared with MTX, irrespective of disease
duration stratification (data not shown).
Safety analysis
A comprehensive analysis of safety data from this study
has been reported elsewhere.23 Table 2 presents TEAEs,
discontinuations due to AEs, SIEs, SAEs and deaths by
disease duration. No meaningful differences were
observed between patients with early and established RA
with respect to all the safety parameters assessed.
DISCUSSION
This post hoc analysis, comparing treatment response in
MTX-naive patients receiving tofacitinib 5 or 10 mg two
times a day monotherapy or MTX monotherapy, has
shown that for signs and symptoms, responses at month
24 were statistically significantly greater in patients with
early RA versus established RA for patients receiving
tofacitinib 5 mg two times a day. In general, numerically
similar clinical and functional responses were observed
in patients with early RA compared with patients with
established RA for those treated with tofacitinib 10 mg
two times a day and MTX. Consistent with the results of
the primary analysis of all randomised and treated
patients,23 we observed that MTX-naive patients with
early or established RA showed significant reductions in
the signs and symptoms of RA, improvements in physical
functioning and inhibition of radiographic progression
when treated with tofacitinib monotherapy (5 or 10 mg
two times a day) compared with MTX monotherapy.
Additionally, there were no meaningful differences in
safety parameters seen between patients with early and
established RA.
In subgroup analyses of clinical trials of TNFi therapy
in patients with RA, better outcomes have generally
been demonstrated in patients with early RA compared
with those with established RA.12–14 30 In the current
post hoc analysis, patients with early RA generally
showed similar improvements in clinical and radio-
graphic efficacy end points compared with patients with
established RA at baseline; however, there were signifi-
cant improvements in ACR20/50/70 responses, and
DAS remission and low disease activity in patients with
early RA versus established RA in the tofacitinib 5 mg
two times a day group at month 24, consistent with the
data generated in clinical trials of TNFi therapy. Patients
who received tofacitinib monotherapy had a statistically
greater likelihood of achieving clinical response com-
pared with those who received MTX, whichever tofaciti-
nib dose or disease duration was compared. Baseline
mean vdHmTSS and erosion scores were observed to be
higher in this study in patients with longer compared
with shorter disease duration, as expected, with
increased joint damage in established RA that has not
been treated effectively.
It has been postulated that there is a window of oppor-
tunity during which it may be possible to prevent joint
damage with early and aggressive treatment of RA.7 9
The American College of Rheumatology now defines
early disease as symptoms of <6 months;31 however, it
should be noted that definitions of early RA vary across
clinical trials from <3 months to <3 years.12 14
Furthermore, duration of RA may be challenging to
assess in clinical trials, and may not be consistent across
trials; time may be determined from onset of symptoms,
Figure 2 Radiographic parameters assessed at month 24 in patients with early RA and established RA. *p<0.05; **p<0.01;
***p<0.001; ****p<0.0001 vs MTX within disease duration category. Early and established RA are defined as disease duration
<1 and ≥1 year, respectively. The proportion of patients without radiographic progression was determined based on a change in
vdHmTSS≤0.5. LS, least squares; MTX, methotrexate; RA, rheumatoid arthritis; vdHmTSS, van der Heijde modification of the
total Sharp score.
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onset of swelling or fulfilment of other classification cri-
teria.10 Additionally, consideration must be given to the
duration of this window of opportunity,32 and when it
may close.33
Given the varying disease durations used in defining
early RA in other studies, results for key efficacy
parameters were reviewed for patients with disease dur-
ation <6 months compared with those with disease dur-
ation ≥6 months, to assess the sensitivity of the results to
the selection of the time points for defining early RA.
Although this analysis demonstrated that treatment
response at month 24 in patients treated with tofacitinib
Figure 3 Treatment differences versus MTX in patients with early and established RA at month 24. (A and B) tofacitinib 5 mg
two times a day; (C and D) tofacitinib 10 mg two times a day. Early and established RA are defined as disease duration <1 and
≥1 year, respectively. ACR, American College of Rheumatology response criteria; DAS28-4(ESR), Disease Activity Score in 28
joints, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; LS, least squares; MTX,
methotrexate; RA, rheumatoid arthritis; vdHmTSS, van der Heijde modification of the total Sharp score.
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Figure 4 Clinical and radiographic end points ORs at month 24 for patients with early and established RA. (A) tofacitinib 5 mg
two times a day; (B) tofacitinib 10 mg two times a day; (C) MTX. Early and established RA are defined as disease duration <1
and ≥1 year, respectively. ACR, American College of Rheumatology response criteria; DAS28-4(ESR), Disease Activity Score in
28 joints, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; vdHmTSS, van der Heijde modification of
the total Sharp score.
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5 mg two times a day was higher in patients with shorter
disease duration, no significant difference between early
and established RA was seen in the tofacitinib 10 mg two
times a day or MTX treatment groups. Thus, our post
hoc analysis did not provide any definitive support for
the concept of a window of opportunity. This study was
not designed to address differing responses dependent
on disease duration, and further investigation of the
effect of tofacitinib in early versus established RA is
warranted.
In considering these results in terms of clinical prac-
tice, it could be concluded, in line with the principle of
treating to target, the best results with tofacitinib or
MTX are obtained in patients with early RA. Therefore,
the diagnosis of RA should be made, and treatment
started, as early as possible after the development of
symptoms. If after 3 months of aggressive MTX therapy
(ie, at least 20–25 mg/week) an adequate response is
not observed, or if MTX is not tolerated, then, if pos-
sible, the patient could be switched to tofacitinib mono-
therapy. If a patient has some response to MTX, but not
a significant response, it would be reasonable to add
tofacitinib to MTX. An ongoing Phase 4 study will evalu-
ate an add-on versus switch strategy in patients with RA
with an inadequate response or intolerance to MTX.34
One potential limitation of this post hoc analysis is
that disease duration was defined by the reporting of
time since diagnosis at baseline by the investigator,
rather than any objective criteria. Diagnosis of RA will
vary from clinic to clinic, depending on local practice;
the fact that the mean duration of disease for patients in
the established RA group was around 6 years, but that
these patients were still MTX-naive, highlights the poten-
tial uncertainty around disease duration for some
patients. A further possible limitation is that this analysis
was not prespecified; as such, comparison of tofacitinib
effects with those of MTX within disease duration
groups was not planned. Also, randomisation into the
clinical trial was therefore not stratified by disease dur-
ation; the distribution of patients between groups is
therefore determined by the decision to use disease dur-
ation of <1 and ≥1 year to categorise early versus estab-
lished RA. However, the results of the sensitivity analysis
suggest that the selection of 1 year as a cut-off to define
early RA was not critical.
CONCLUSIONS
Within treatment groups, improvements in signs and
symptoms, physical function and inhibition of progres-
sion of structural damage were generally similar between
patients with early RA and patients with established RA,
although statistically significantly greater improvements
in signs and symptoms of disease were observed at month
24 with tofacitinib 5 mg two times a day monotherapy in
patients with early RA versus those with established RA.
Tofacitinib 5 and 10 mg two times a day monotherapy
significantly improved signs and symptoms and physical
function, and inhibited the progression of structural
damage, in MTX-naive patients with early or established
RA, as compared with MTX monotherapy. No meaning-
ful differences in safety end points were observed
between early and established RA subpopulations.
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Table 2 Safety data: number of patients with AEs
Duration of RA
Tofacitinib 5 mg two
times a day
Tofacitinib 10 mg two
times a day MTX
Early
(n=201)
Established
(n=172)
Early
(n=207)
Established
(n=190)
Early
(n=107)
Established
(n=79)
TEAEs, n (%) 165 (82.1) 132 (76.7) 175 (84.5) 159 (83.7) 83 (77.6) 64 (81.0)
Discontinuations due to AEs, n (%) 22 (10.9) 18 (10.5) 21 (10.1) 20 (10.5) 14 (13.1) 11 (13.9)
Serious infections, n (%) 3 (1.5) 8 (4.7) 4 (1.9) 4 (2.1) 3 (2.8) 2 (2.5)
SAEs, n (%)* 17 (8.5) 22 (12.8) 15 (7.2) 26 (13.7) 11 (10.3) 11 (13.9)
Deaths, n (%)*
Within 30-day rule 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Outside 30-day rule 2 (1.0) 1 (0.6) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Early RA was defined as disease duration <1 year, and established RA was defined as disease duration ≥1 year.
*Two patients had SAEs and one patient died before being randomised to treatment. Therefore, these events are not included in the above
table.
AE, adverse event; MTX, methotrexate; n, number of patients; RA, rheumatoid arthritis; SAE, serious adverse event; TEAE, treatment-
emergent adverse event.
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